Scilex Holding Co [Rocket]

Date Filed

Type

Description

11/17/2022

Certificate of designation filed, Director compensation was amended/approved

Docs:

"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"State of Delaware Secretary of State Division of Corporations Delivered 08:01 AM 11/10/2022 FILED 08:01 AM 11/10/2022 SR 20223985377 - File Number 7129127 RESTATED CERTIFICATE OF INCORPORATION OF SCILEX HOLDING COMPANY a Delaware corporation",
"CERTIFICATE OF DESIGNATIONS OF SCILEX HOLDING COMPANY a Delaware corporation",
"BYLAWS OF SCILEX HOLDING COMPANY",
"AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT",
"INDEMNIFICATION AGREEMENT",
"SCILEX HOLDING COMPANY 2022 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: October 17, 2022 APPROVED BY THE STOCKHOLDERS: November 9, 2022 EFFECTIVE DATE: November 9, 2022 1. GENERAL. Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. Available Awards. The Plan provides for the grant of the following Awards: Incentive Stock Options; Nonstatutory Stock Options; SARs; Restricted Stock Awards; RSU Awards; Performance Awards; and Other Aw...",
"SCILEX HOLDING COMPANY STOCK OPTION GRANT NOTICE",
"SCILEX HOLDING COMPANY RSU AWARD GRANT NOTICE",
"SCILEX HOLDING COMPANY 2022 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: October 17, 2022 APPROVED BY THE STOCKHOLDERS: November 9, 2022 EFFECTIVE DATE: November 9, 2022 1. GENERAL; PURPOSE. The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. The Plan includes two components: a 423 Component and a Non-423 Component. The Company intends the 423 Component to qualify as..."

03/18/2022

8-K

Director compensation was amended/approved

Docs:

"Vickers Vantage Corp. I 1 Harbourfront Avenue, #16-06 Keppel Bay Tower, Singapore 098632 Singapore",
"AGREEMENT AND PLAN OF MERGER",
"SPONSOR SUPPORT AGREEMENT",
"COMPANY STOCKHOLDER SUPPORT AGREEMENT",
"SCILEX HOLDING COMPANY, A MAJORITY-OWNED SUBSIDIARY OF SORRENTO THERAPEUTICS, INC., TO BECOME PUBLICLY TRADED THROUGH A MERGER WITH VICKERS VANTAGE CORP. I ● Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds before expenses, assuming no redemptions from Vickers Vantage Corp. I’ s existing public shareholders, which would provide the current stockholders of Scilex an estimated ownership of approximately 88% of the outstanding shares of the Combined Company. Merger expected to close by the third quarter of 2022, and the Combined Company’ s common stock is expected to be listed on Nasdaq under the new ticker symbol “SCLX” ● Funds will be used ...",
"Exhiibit 99.2 FOR IMMEDIATE RELEASE Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity ● SP-102 , with 401 patients enrolled in the C.L.E.A.R. trial experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with highly statistically significant improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS Mean difference -1.08 , with a p-value ● SP-102 showed continued reduction of pain beyond one month, and the median time to open-label repeat injection was ...",
"Investor Presentation"